Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE AMAYA

Allopathic & Osteopathic Physicians General Practice

NPI
1811093735
CMS profile
1098197
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$14.69

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $14.69 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $14.69 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE AMAYA

NPI 1811093735 · CMS profile ID 1098197

Allopathic & Osteopathic Physicians / General Practice

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1811093735?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE AMAYA, NPI 1811093735, CMS profile ID 1098197. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811093735?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JORGE AMAYA, NPI 1811093735, CMS profile ID 1098197. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811093735?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JORGE AMAYA, NPI 1811093735, CMS profile ID 1098197, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1811093735?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $14.69 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $14.6901/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736037905 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $14.69 1
PY2024 $275.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $149.40 4
PY2025 Principal investigator $9,605,837.68 36
PY2024 Principal investigator $2,945,685.04 45
PY2023 Principal investigator $1,445,733.23 46
PY2022 Principal investigator $30,954.76 9
PY2021 Principal investigator $21,517.30 3
PY2020 Principal investigator $169,560.43 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $14,885.00 10/30/2024 Non-covered Recipient Entity
D AND H NATIONAL RESEARCH CENTERS INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133390006
Principal investigator 1 Genentech, Inc. $4,068.00 10/18/2024 Non-covered Recipient Entity
D AND H NATIONAL RESEARCH CENTERS INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133390004
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $16,000.00 10/16/2024 Non-covered Recipient Entity
Elias Research Associates LLC
A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution No dispute reported 06/30/2026 1150067597
Principal investigator 1 Genentech, Inc. $1,321.00 10/09/2024 Non-covered Recipient Entity
D AND H NATIONAL RESEARCH CENTERS INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133390002
Principal investigator 1 ABBVIE INC. $3,000.00 10/02/2024 Non-covered Recipient Entity
D&H NATIONAL RESEARCH CENTERS INC
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1100745146
Principal investigator 1 Genentech, Inc. $622.00 09/25/2024 Non-covered Recipient Entity
D AND H NATIONAL RESEARCH CENTERS INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133389998
Principal investigator 1 Genentech, Inc. $1,189.00 09/18/2024 Non-covered Recipient Entity
D AND H NATIONAL RESEARCH CENTERS INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133389994
Principal investigator 1 Genentech, Inc. $1,200.00 09/06/2024 Non-covered Recipient Entity
D AND H NATIONAL RESEARCH CENTERS INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133390000
Principal investigator 1 ABBVIE INC. $2,675.00 09/05/2024 Non-covered Recipient Entity
D&H NATIONAL RESEARCH CENTERS INC
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1100741226
Principal investigator 1 Genentech, Inc. $1,222.00 08/30/2024 Non-covered Recipient Entity
D AND H NATIONAL RESEARCH CENTERS INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133389992
Principal investigator 1 Genentech, Inc. $22.00 08/14/2024 Non-covered Recipient Entity
D AND H NATIONAL RESEARCH CENTERS INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133389996
Principal investigator 1 PFIZER INC. $3,000.00 07/24/2024 Non-covered Recipient Entity
DH National Research Centers INC
A PHASE 23 TWOPART STUDY TO EVALUATE THE EFFICACY AND LONGTERM SAFETY WITH ORAL ETRASIMOD 2 MG ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATETOSEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE No dispute reported 06/30/2026 1131044683
Principal investigator 1 PFIZER INC. $3,000.00 07/23/2024 Non-covered Recipient Entity
DH National Research Centers INC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1131044763
Principal investigator 1 Amgen Inc. $2,600,332.08 07/05/2024 Non-covered Recipient Entity
D&H NATIONAL RESEARCH CENTERS
P4 Uncontrolled Gout FORWARD II No dispute reported 06/30/2026 1096314013
Principal investigator 1 AstraZeneca UK Limited $35,138.95 06/12/2024 Non-covered Recipient Entity
D AND H NATIONAL RESEARCH CENTERS, INC
Phase I, Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8630 in Healthy Adult Subjects (Part A) and Adults with Asthma on Medium to High Dose Inhaled Corticosteroids and Long-acting Beta-agonists (Part B) No dispute reported 06/30/2026 1110839238
Principal investigator 1 ABBVIE INC. $1,075.00 06/06/2024 Non-covered Recipient Entity
D&H NATIONAL RESEARCH CENTERS INC
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1100722414
Principal investigator 1 ABBVIE INC. $1,168.00 06/05/2024 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1100721132
Principal investigator 1 Amgen Inc. $121,914.57 06/05/2024 Non-covered Recipient Entity
D AND H NATIONAL RESEARCH CENTERS INC
P4 Uncontrolled Gout FORWARD II No dispute reported 06/30/2026 1096314005
Principal investigator 1 PFIZER INC. $1,109.16 05/15/2024 Non-covered Recipient Entity
DH National Research Centers INC
A PHASE 23 TWOPART STUDY TO EVALUATE THE EFFICACY AND LONGTERM SAFETY WITH ORAL ETRASIMOD 2 MG ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATETOSEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE No dispute reported 06/30/2026 1131075068
Principal investigator 1 ABBVIE INC. $6,331.00 05/09/2024 Non-covered Recipient Entity
D&H NATIONAL RESEARCH CENTERS INC
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1100717624
Principal investigator 1 ABBVIE INC. $6,862.00 05/08/2024 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1100716456
Principal investigator 1 PFIZER INC. $858.00 04/27/2024 Non-covered Recipient Entity
DH National Research Centers INC
A PHASE 23 TWOPART STUDY TO EVALUATE THE EFFICACY AND LONGTERM SAFETY WITH ORAL ETRASIMOD 2 MG ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATETOSEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE No dispute reported 06/30/2026 1131092171
Principal investigator 1 PFIZER INC. $2,755.48 04/26/2024 Non-covered Recipient Entity
DH National Research Centers INC
A PHASE 23 TWOPART STUDY TO EVALUATE THE EFFICACY AND LONGTERM SAFETY WITH ORAL ETRASIMOD 2 MG ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATETOSEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE No dispute reported 06/30/2026 1131091559
Principal investigator 1 GlaxoSmithKline, LLC. $554.44 04/24/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127515570
Principal investigator 1 Amgen Inc. $1,456.00 04/20/2024 Non-covered Recipient Entity
D AND H NATIONAL RESEARCH CENTERS
VOYAGER P3 AD Vaccine Study No dispute reported 06/30/2026 1096316386
Principal investigator 1 ABBVIE INC. $8,752.00 04/08/2024 Non-covered Recipient Entity
D&H NATIONAL RESEARCH CENTERS INC
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1100713322
Principal investigator 1 PFIZER INC. $21,479.58 04/05/2024 Non-covered Recipient Entity
DH National Research Centers INC
A PHASE 23 TWOPART STUDY TO EVALUATE THE EFFICACY AND LONGTERM SAFETY WITH ORAL ETRASIMOD 2 MG ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATETOSEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE No dispute reported 06/30/2026 1131092166
Principal investigator 1 ABBVIE INC. $7,315.00 04/04/2024 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1100711968
Principal investigator 1 PFIZER INC. $1,216.54 03/21/2024 Non-covered Recipient Entity
DH National Research Centers INC
A PHASE 23 TWOPART STUDY TO EVALUATE THE EFFICACY AND LONGTERM SAFETY WITH ORAL ETRASIMOD 2 MG ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATETOSEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE No dispute reported 06/30/2026 1131105001
Principal investigator 1 PFIZER INC. $5,194.80 03/15/2024 Non-covered Recipient Entity
DH National Research Centers INC
A PHASE 23 TWOPART STUDY TO EVALUATE THE EFFICACY AND LONGTERM SAFETY WITH ORAL ETRASIMOD 2 MG ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATETOSEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE No dispute reported 06/30/2026 1131104969
Principal investigator 1 ABBVIE INC. $3,500.00 03/14/2024 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1100708385
Principal investigator 1 PFIZER INC. $1,216.54 03/09/2024 Non-covered Recipient Entity
DH National Research Centers INC
A PHASE 23 TWOPART STUDY TO EVALUATE THE EFFICACY AND LONGTERM SAFETY WITH ORAL ETRASIMOD 2 MG ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATETOSEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE No dispute reported 06/30/2026 1131104991
Principal investigator 1 PFIZER INC. $2,597.40 02/22/2024 Non-covered Recipient Entity
DH National Research Centers INC
A PHASE 23 TWOPART STUDY TO EVALUATE THE EFFICACY AND LONGTERM SAFETY WITH ORAL ETRASIMOD 2 MG ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATETOSEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE No dispute reported 06/30/2026 1131104963
Principal investigator 1 Genentech, Inc. $3,424.00 02/21/2024 Non-covered Recipient Entity
D AND H NATIONAL RESEARCH CENTERS INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133389990
Principal investigator 1 Amgen Inc. $590.52 02/13/2024 Non-covered Recipient Entity
D AND H NATIONAL RESEARCH CENTERS
VOYAGER P3 AD Vaccine Study No dispute reported 06/30/2026 1096316388
Principal investigator 1 PFIZER INC. $9,800.00 02/09/2024 Non-covered Recipient Entity
DH National Research Centers INC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1131104995
Principal investigator 1 ABBVIE INC. $6,490.00 02/08/2024 Non-covered Recipient Entity
D&H NATIONAL RESEARCH CENTERS INC
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1100703322
Principal investigator 1 PFIZER INC. $2,597.40 02/06/2024 Non-covered Recipient Entity
DH National Research Centers INC
A PHASE 23 TWOPART STUDY TO EVALUATE THE EFFICACY AND LONGTERM SAFETY WITH ORAL ETRASIMOD 2 MG ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATETOSEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE No dispute reported 06/30/2026 1131104958
Principal investigator 1 ABBVIE INC. $7,037.00 02/01/2024 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1100701608
Principal investigator 1 GlaxoSmithKline, LLC. $1,800.00 01/25/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127515568
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 01/25/2024 Non-covered Recipient Entity
PHARMASEEK LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127515572
Principal investigator 1 Amgen Inc. $1,322.50 01/23/2024 Non-covered Recipient Entity
D H NATIONAL RESEARCH CENTERS INC
P4 Uncontrolled Gout AGILE No dispute reported 06/30/2026 1096313849
Principal investigator 1 ABBVIE INC. $12,557.00 01/11/2024 Non-covered Recipient Entity
D&H NATIONAL RESEARCH CENTERS INC
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1100699925
Principal investigator 1 ABBVIE INC. $13,603.00 01/04/2024 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1100698499
Principal investigator 1 PFIZER INC. $2,433.08 01/04/2024 Non-covered Recipient Entity
DH National Research Centers INC
A PHASE 23 TWOPART STUDY TO EVALUATE THE EFFICACY AND LONGTERM SAFETY WITH ORAL ETRASIMOD 2 MG ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATETOSEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE No dispute reported 06/30/2026 1131106373